Targeting the CaN/FoxO1/FABP4 Pathway in SERCA2 Dysfunction-Driven Atherosclerosis

Study Background and Research Question

Atherosclerosis remains a leading cause of cardiovascular morbidity and mortality worldwide, characterized by chronic inflammation and progressive lipid accumulation in the arterial wall. Central to the disease's pathogenesis is the transformation of macrophages into lipid-laden foam cells, which accelerate plaque formation and instability. While the contribution of dysregulated lipid metabolism and inflammatory signaling in atherogenesis is well established, the precise molecular cascades linking endoplasmic reticulum (ER) stress and altered calcium homeostasis to foam cell formation have been incompletely defined.

SERCA2 (sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2) is a calcium pump critical for maintaining ER calcium balance. Emerging evidence suggests that dysfunction of SERCA2, particularly through the pathogenic C674S mutation, exacerbates atherosclerosis by promoting ER stress, inflammation, and disturbed lipid handling in both macrophages and endothelial cells. This study by Zhu et al. (reference study) sought to clarify whether SERCA2 dysfunction directly drives atherogenesis via derangements in fatty acid metabolism and to identify actionable molecular targets within this axis.

Key Innovation from the Reference Study

The core innovation of this work lies in its elucidation of the calcineurin (CaN)/forkhead box O1 (FoxO1)/fatty acid binding protein 4 (FABP4) signaling pathway as a mechanistic bridge between SERCA2 dysfunction and foam cell formation. While previous research has implicated both ER stress and FABP4 in atherosclerosis, this study systematically demonstrates that SERCA2 dysfunction upregulates calcineurin, promoting the nuclear translocation of FoxO1 and subsequent transcriptional activation of FABP4 in bone marrow-derived macrophages (BMDMs). This cascade enhances fatty acid synthesis and uptake, fostering foam cell development and plaque progression.

Importantly, the authors further show that pharmacological inhibition or genetic partial deficiency of FABP4 disrupts this pathological signaling axis, normalizes lipid handling, and significantly reduces atherosclerotic lesion burden. These findings pinpoint FABP4 as a tractable and specific target for interventions aiming to halt or reverse atherosclerotic progression in settings of SERCA2 dysfunction.

Methods and Experimental Design Insights

To model SERCA2 dysfunction, the researchers generated heterozygous knock-in (SKI) mice carrying the C674S mutation in the SERCA2 gene. These animals, along with wild-type littermates, underwent comprehensive metabolic and histological characterization. Serum metabolomics provided a global view of lipid and fatty acid alterations, while aortic root and whole aorta samples were subjected to detailed histological analysis to quantify atherosclerotic lesions.

Crucially, BMDMs isolated from SKI and wild-type mice served as the primary cellular system to dissect molecular mechanisms. Protein expression analyses, lipid uptake assays, and foam cell quantification were complemented by targeted pharmacological interventions. The study utilized selective inhibitors for FoxO1 and FABP4, including the well-characterized small-molecule FABP4 inhibitor BMS 309403, to evaluate their impact on lipid metabolism and foam cell formation.

Key markers such as ABCA1/ABCG1 (cholesterol efflux), ACAT2 (cholesteryl esterification), and FAS (fatty acid synthesis) were assessed to delineate the downstream metabolic consequences of pathway modulation.

Core Findings and Why They Matter

The study produced several interlocking findings that advance our understanding of atherosclerosis pathobiology:

• SERCA2 dysfunction (C674S mutation) triggers upregulation of calcineurin in BMDMs, leading to nuclear translocation of FoxO1 and increased transcription of FABP4 (reference study).
• Elevated FABP4 expression in macrophages promotes fatty acid synthesis and lipid uptake, resulting in enhanced foam cell formation and the progression of atherosclerotic lesions.
• Inhibition of the CaN/FoxO1/FABP4 pathway, via either selective pharmacological agents or partial genetic deficiency of FABP4, restores balanced lipid metabolism and significantly attenuates atherosclerotic plaque development.
• These protective effects are tightly linked to normalization of fatty acid and cholesterol handling, as demonstrated by improved expression of cholesterol efflux transporters and reduced accumulation of cholesteryl esters in treated cells and tissues.

Collectively, these findings highlight FABP4 not only as a biomarker of dysfunctional lipid metabolism in atherosclerosis but as a causal driver whose inhibition offers a compelling therapeutic avenue, especially in conditions marked by ER calcium pump dysfunction.

Comparison with Existing Internal Articles

These results reinforce and expand upon insights from several recent reviews and workflow articles. For instance, the internal review "BMS 309403: Advanced Insights into FABP4 Inhibition for Atherosclerosis and Metabolic Disease Research" details the molecular rationale and translational promise of targeting FABP4, with BMS 309403 emerging as a potent, selective inhibitor that can dissect FABP4's role in both lipid metabolism and inflammatory signaling.

Similarly, the article "BMS 309403: Precision FABP4 Inhibitor Workflows in Atherosclerosis" provides practical protocol guidance for deploying BMS 309403 in preclinical models, aligning with the current study's demonstration of its utility in correcting lipid dysregulation via the CaN/FoxO1/FABP4 axis. The mechanistic clarity offered by the Zhu et al. study strengthens the argument for FABP4 as a nodal point in atherosclerosis research and validates the use of selective inhibitors such as BMS 309403 for both methodological and translational research programs.

Notably, the study provides direct experimental evidence bridging the calcineurin/FoxO1/FABP4 pathway to atherogenesis, which had previously been hypothesized but not fully mapped in the context of SERCA2 dysfunction. This mechanistic bridge is further contextualized in "Inhibiting the CaN/FoxO1/FABP4 Pathway to Prevent Atherosclerosis", which summarizes the translational significance of FABP4 inhibition in this pathway.

Limitations and Transferability

While the study's genetic and pharmacological models offer robust mechanistic insight, certain limitations warrant consideration. The use of heterozygous SKI mice models a specific form of SERCA2 dysfunction, and while relevant to human pathology, may not capture all aspects of cardiovascular disease diversity. The study's reliance on murine macrophages and atherosclerosis models also invites caution when extrapolating to human disease, where additional regulatory layers and environmental factors are at play.

Moreover, although the pharmacological inhibition of FABP4 (using BMS 309403) demonstrated efficacy in preclinical models, questions remain regarding the long-term safety, specificity, and translational feasibility of such interventions in humans. Off-target effects, compensatory metabolic pathways, and tissue-specific responses have yet to be fully explored.

Protocol Parameters

• Genetic Model: Use heterozygous SERCA2 C674S knock-in (SKI) mice to model ER calcium pump dysfunction in vivo.
• BMDM Isolation: Harvest bone marrow-derived macrophages from SKI and wild-type mice for mechanistic in vitro assays.
• Pharmacological Inhibitor Treatment: Apply BMS 309403 at working concentrations of 1–25 μM, dissolved in DMSO or ethanol, to BMDMs to selectively inhibit FABP4 (product information).
• Histological Assessment: Analyze aortic root and entire aorta for lesion area quantification and lipid deposition via Oil Red O and H&E staining.
• Metabolomic Profiling: Collect serum for targeted and untargeted analysis of fatty acid, cholesterol, and cholesteryl ester species.
• Protein and Gene Expression: Assess pathway activation and metabolic enzyme expression by Western blot and qPCR (e.g., calcineurin, FoxO1, FABP4, ABCA1, FAS).

Research Support Resources

For researchers aiming to replicate or extend these findings, selective inhibition of FABP4 remains the most direct strategy to probe the CaN/FoxO1/FABP4 axis in atherosclerosis and metabolic disease models. BMS 309403 (SKU B7794) is a potent and selective FABP4 inhibitor, suitable for both in vitro and in vivo experimental workflows. Its high specificity and well-characterized solubility profile (soluble in DMSO and ethanol) make it an adaptable choice for studies on lipid metabolism, inflammation, and cardiovascular pathophysiology, as described in the referenced study and supporting literature. For best results, consult product guidance for storage and working concentrations, and align experimental protocols with recent mechanistic advances in the field.